DALLAS, TX -- April 30th, 2024 - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Potentially Transformative therapies for Generalized Anxiety Disorder (GAD)." This report explores the pervasive issue of GAD, a condition affecting millions worldwide, and potentially transformative therapies which will change the landscape of future treatments.
The World Health Organization (WHO) estimates that GAD impacts approximately 3.6% of the global population. The global market for GAD treatment is projected to reach a value of $4B+ by 2033, with a 9% CAGR from 2023 onwards. This growth is propelled by several factors, including the expanding prevalence of anxiety disorders, advancements in medication, and a growing recognition of the importance of mental health.
Stonegate's research focused on over 40 companies in the GAD space, resulting in the identification of three companies with the potential to revolutionize anxiety treatment. We believe Mindmed, Incannex (NASDAQ: IXHL), and Compass Pathways are poised to revolutionize the landscape of anxiety treatment, particularly in the realm of generalized anxiety disorder.
Our mission at Stonegate Healthcare Partners is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach is centered on comprehensive and comparative analyses in specific healthcare fields. We strive to pinpoint programs that align closely with our strategic vision for the space and focus on technologies with the greatest potential for disruption. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, further enabling a current understanding of unmet needs and emerging disruptive technologies.
